NICE End-of-Life criteria | SMC End-of-Life and Rarity criteria |
---|---|
the treatment is indicated for patients with a short life expectancy, normally less than 24 months; | EoL: medicine to treat a condition at a stage that usually leads to death within 3 years. |
and | |
the treatment offers an extension to life, normally of at least an additional 3 months; | |
and | or |
for small patient populations normally not exceeding a cumulative total of 7000 for all licensed indications in England (ie 1 in 7700)* | Orphan: medicine to treat a condition affecting fewer than 2500 people in a population of 5 million) (ie 1 in 2000). |
or | |
Ultra-orphan: medicine to treat a condition with a prevalence of 1 in 50,000 or less. |